Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
Chronic Disease
Cytokines
/ antagonists & inhibitors
Female
Humans
Immunosuppressive Agents
/ therapeutic use
Male
Middle Aged
Molecular Targeted Therapy
Network Meta-Analysis
Placebos
/ therapeutic use
Psoriasis
/ drug therapy
Randomized Controlled Trials as Topic
Remission Induction
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
19 04 2021
19 04 2021
Historique:
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Several randomised controlled trials (RCTs) have compared the efficacy of the different systemic treatments in psoriasis against placebo. However, the relative benefit of these treatments remains unclear due to the limited number of trials comparing them directly head-to-head, which is why we chose to conduct a network meta-analysis. To compare the efficacy and safety of non-biological systemic agents, small molecules, and biologics for people with moderate-to-severe psoriasis using a network meta-analysis, and to provide a ranking of these treatments according to their efficacy and safety. For this living systematic review we updated our searches of the following databases monthly to September 2020: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase. We searched two trials registers to the same date. We checked the reference lists of included studies and relevant systematic reviews for further references to eligible RCTs. Randomised controlled trials (RCTs) of systemic treatments in adults (over 18 years of age) with moderate-to-severe plaque psoriasis or psoriatic arthritis whose skin had been clinically diagnosed with moderate-to-severe psoriasis, at any stage of treatment, in comparison to placebo or another active agent. The primary outcomes of this review were: the proportion of participants who achieved clear or almost clear skin, that is, at least Psoriasis Area and Severity Index (PASI) 90 at induction phase (from 8 to 24 weeks after the randomisation), and the proportion of participants with serious adverse events (SAEs) at induction phase. We did not evaluate differences in specific adverse events. Several groups of two review authors independently undertook study selection, data extraction, 'Risk of bias' assessment, and analyses. We synthesised the data using pair-wise and network meta-analysis (NMA) to compare the treatments of interest and rank them according to their effectiveness (as measured by the PASI 90 score) and acceptability (the inverse of serious adverse events). We assessed the certainty of the body of evidence from the NMA for the two primary outcomes and all comparisons, according to CINeMA, as either very low, low, moderate, or high. We contacted study authors when data were unclear or missing. We used the surface under the cumulative ranking curve (SUCRA) to infer on treatment hierarchy: 0% (treatment is the worst for effectiveness or safety) to 100% (treatment is the best for effectiveness or safety). We included 158 studies (18 new studies for the update) in our review (57,831 randomised participants, 67.2% men, mainly recruited from hospitals). The overall average age was 45 years; the overall mean PASI score at baseline was 20 (range: 9.5 to 39). Most of these studies were placebo-controlled (58%), 30% were head-to-head studies, and 11% were multi-armed studies with both an active comparator and a placebo. We have assessed a total of 20 treatments. In all, 133 trials were multicentric (two to 231 centres). All but two of the outcomes included in this review were limited to the induction phase (assessment from 8 to 24 weeks after randomisation). We assessed many studies (53/158) as being at high risk of bias; 25 were at an unclear risk, and 80 at low risk. Most studies (123/158) declared funding by a pharmaceutical company, and 22 studies did not report their source of funding. Network meta-analysis at class level showed that all of the interventions (non-biological systemic agents, small molecules, and biological treatments) were significantly more effective than placebo in reaching PASI 90. At class level, in reaching PASI 90, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more effective than the small molecules and the non-biological systemic agents. At drug level, infliximab, ixekizumab, secukinumab, brodalumab, risankizumab and guselkumab were significantly more effective in reaching PASI 90 than ustekinumab and three anti-TNF alpha agents: adalimumab, certolizumab, and etanercept. Ustekinumab and adalimumab were significantly more effective in reaching PASI 90 than etanercept; ustekinumab was more effective than certolizumab, and the clinical effectiveness of ustekinumab and adalimumab was similar. There was no significant difference between tofacitinib or apremilast and three non-biological drugs: fumaric acid esters (FAEs), ciclosporin and methotrexate. Network meta-analysis also showed that infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab, and brodalumab outperformed other drugs when compared to placebo in reaching PASI 90. The clinical effectiveness of these drugs was similar, except for ixekizumab which had a better chance of reaching PASI 90 compared with secukinumab, guselkumab and brodalumab. The clinical effectiveness of these seven drugs was: infliximab (versus placebo): risk ratio (RR) 50.29, 95% confidence interval (CI) 20.96 to 120.67, SUCRA = 93.6; high-certainty evidence; ixekizumab (versus placebo): RR 32.48, 95% CI 27.13 to 38.87; SUCRA = 90.5; high-certainty evidence; risankizumab (versus placebo): RR 28.76, 95% CI 23.96 to 34.54; SUCRA = 84.6; high-certainty evidence; bimekizumab (versus placebo): RR 58.64, 95% CI 3.72 to 923.86; SUCRA = 81.4; high-certainty evidence; secukinumab (versus placebo): RR 25.79, 95% CI 21.61 to 30.78; SUCRA = 76.2; high-certainty evidence; guselkumab (versus placebo): RR 25.52, 95% CI 21.25 to 30.64; SUCRA = 75; high-certainty evidence; and brodalumab (versus placebo): RR 23.55, 95% CI 19.48 to 28.48; SUCRA = 68.4; moderate-certainty evidence. Conservative interpretation is warranted for the results for bimekizumab (as well as mirikizumab, tyrosine kinase 2 inhibitor, acitretin, ciclosporin, fumaric acid esters, and methotrexate), as these drugs, in the NMA, have been evaluated in few trials. We found no significant difference between any of the interventions and the placebo for the risk of SAEs. Nevertheless, the SAE analyses were based on a very low number of events with low to moderate certainty for all the comparisons. Thus, the results have to be viewed with caution and we cannot be sure of the ranking. For other efficacy outcomes (PASI 75 and Physician Global Assessment (PGA) 0/1) the results were similar to the results for PASI 90. Information on quality of life was often poorly reported and was absent for several of the interventions. Our review shows that compared to placebo, the biologics infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab and brodalumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis on the basis of moderate- to high-certainty evidence. This NMA evidence is limited to induction therapy (outcomes were measured from 8 to 24 weeks after randomisation) and is not sufficient for evaluation of longer-term outcomes in this chronic disease. Moreover, we found low numbers of studies for some of the interventions, and the young age (mean age of 45 years) and high level of disease severity (PASI 20 at baseline) may not be typical of patients seen in daily clinical practice. Another major concern is that short-term trials provide scanty and sometimes poorly-reported safety data and thus do not provide useful evidence to create a reliable risk profile of treatments. We found no significant difference in the assessed interventions and placebo in terms of SAEs, and the evidence for all the interventions was of low to moderate quality. In order to provide long-term information on the safety of the treatments included in this review, it will also be necessary to evaluate non-randomised studies and postmarketing reports released from regulatory agencies. In terms of future research, randomised trials directly comparing active agents are necessary once high-quality evidence of benefit against placebo is established, including head-to-head trials amongst and between non-biological systemic agents and small molecules, and between biological agents (anti-IL17 versus anti-IL23, anti-IL23 versus anti-IL12/23, anti-TNF alpha versus anti-IL12/23). Future trials should also undertake systematic subgroup analyses (e.g. assessing biological-naïve participants, baseline psoriasis severity, presence of psoriatic arthritis, etc.). Finally, outcome measure harmonisation is needed in psoriasis trials, and researchers should look at the medium- and long-term benefit and safety of the interventions and the comparative safety of different agents. Editorial note: This is a living systematic review. Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
Sections du résumé
BACKGROUND
Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Several randomised controlled trials (RCTs) have compared the efficacy of the different systemic treatments in psoriasis against placebo. However, the relative benefit of these treatments remains unclear due to the limited number of trials comparing them directly head-to-head, which is why we chose to conduct a network meta-analysis.
OBJECTIVES
To compare the efficacy and safety of non-biological systemic agents, small molecules, and biologics for people with moderate-to-severe psoriasis using a network meta-analysis, and to provide a ranking of these treatments according to their efficacy and safety.
SEARCH METHODS
For this living systematic review we updated our searches of the following databases monthly to September 2020: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase. We searched two trials registers to the same date. We checked the reference lists of included studies and relevant systematic reviews for further references to eligible RCTs.
SELECTION CRITERIA
Randomised controlled trials (RCTs) of systemic treatments in adults (over 18 years of age) with moderate-to-severe plaque psoriasis or psoriatic arthritis whose skin had been clinically diagnosed with moderate-to-severe psoriasis, at any stage of treatment, in comparison to placebo or another active agent. The primary outcomes of this review were: the proportion of participants who achieved clear or almost clear skin, that is, at least Psoriasis Area and Severity Index (PASI) 90 at induction phase (from 8 to 24 weeks after the randomisation), and the proportion of participants with serious adverse events (SAEs) at induction phase. We did not evaluate differences in specific adverse events.
DATA COLLECTION AND ANALYSIS
Several groups of two review authors independently undertook study selection, data extraction, 'Risk of bias' assessment, and analyses. We synthesised the data using pair-wise and network meta-analysis (NMA) to compare the treatments of interest and rank them according to their effectiveness (as measured by the PASI 90 score) and acceptability (the inverse of serious adverse events). We assessed the certainty of the body of evidence from the NMA for the two primary outcomes and all comparisons, according to CINeMA, as either very low, low, moderate, or high. We contacted study authors when data were unclear or missing. We used the surface under the cumulative ranking curve (SUCRA) to infer on treatment hierarchy: 0% (treatment is the worst for effectiveness or safety) to 100% (treatment is the best for effectiveness or safety).
MAIN RESULTS
We included 158 studies (18 new studies for the update) in our review (57,831 randomised participants, 67.2% men, mainly recruited from hospitals). The overall average age was 45 years; the overall mean PASI score at baseline was 20 (range: 9.5 to 39). Most of these studies were placebo-controlled (58%), 30% were head-to-head studies, and 11% were multi-armed studies with both an active comparator and a placebo. We have assessed a total of 20 treatments. In all, 133 trials were multicentric (two to 231 centres). All but two of the outcomes included in this review were limited to the induction phase (assessment from 8 to 24 weeks after randomisation). We assessed many studies (53/158) as being at high risk of bias; 25 were at an unclear risk, and 80 at low risk. Most studies (123/158) declared funding by a pharmaceutical company, and 22 studies did not report their source of funding. Network meta-analysis at class level showed that all of the interventions (non-biological systemic agents, small molecules, and biological treatments) were significantly more effective than placebo in reaching PASI 90. At class level, in reaching PASI 90, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more effective than the small molecules and the non-biological systemic agents. At drug level, infliximab, ixekizumab, secukinumab, brodalumab, risankizumab and guselkumab were significantly more effective in reaching PASI 90 than ustekinumab and three anti-TNF alpha agents: adalimumab, certolizumab, and etanercept. Ustekinumab and adalimumab were significantly more effective in reaching PASI 90 than etanercept; ustekinumab was more effective than certolizumab, and the clinical effectiveness of ustekinumab and adalimumab was similar. There was no significant difference between tofacitinib or apremilast and three non-biological drugs: fumaric acid esters (FAEs), ciclosporin and methotrexate. Network meta-analysis also showed that infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab, and brodalumab outperformed other drugs when compared to placebo in reaching PASI 90. The clinical effectiveness of these drugs was similar, except for ixekizumab which had a better chance of reaching PASI 90 compared with secukinumab, guselkumab and brodalumab. The clinical effectiveness of these seven drugs was: infliximab (versus placebo): risk ratio (RR) 50.29, 95% confidence interval (CI) 20.96 to 120.67, SUCRA = 93.6; high-certainty evidence; ixekizumab (versus placebo): RR 32.48, 95% CI 27.13 to 38.87; SUCRA = 90.5; high-certainty evidence; risankizumab (versus placebo): RR 28.76, 95% CI 23.96 to 34.54; SUCRA = 84.6; high-certainty evidence; bimekizumab (versus placebo): RR 58.64, 95% CI 3.72 to 923.86; SUCRA = 81.4; high-certainty evidence; secukinumab (versus placebo): RR 25.79, 95% CI 21.61 to 30.78; SUCRA = 76.2; high-certainty evidence; guselkumab (versus placebo): RR 25.52, 95% CI 21.25 to 30.64; SUCRA = 75; high-certainty evidence; and brodalumab (versus placebo): RR 23.55, 95% CI 19.48 to 28.48; SUCRA = 68.4; moderate-certainty evidence. Conservative interpretation is warranted for the results for bimekizumab (as well as mirikizumab, tyrosine kinase 2 inhibitor, acitretin, ciclosporin, fumaric acid esters, and methotrexate), as these drugs, in the NMA, have been evaluated in few trials. We found no significant difference between any of the interventions and the placebo for the risk of SAEs. Nevertheless, the SAE analyses were based on a very low number of events with low to moderate certainty for all the comparisons. Thus, the results have to be viewed with caution and we cannot be sure of the ranking. For other efficacy outcomes (PASI 75 and Physician Global Assessment (PGA) 0/1) the results were similar to the results for PASI 90. Information on quality of life was often poorly reported and was absent for several of the interventions.
AUTHORS' CONCLUSIONS
Our review shows that compared to placebo, the biologics infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab and brodalumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis on the basis of moderate- to high-certainty evidence. This NMA evidence is limited to induction therapy (outcomes were measured from 8 to 24 weeks after randomisation) and is not sufficient for evaluation of longer-term outcomes in this chronic disease. Moreover, we found low numbers of studies for some of the interventions, and the young age (mean age of 45 years) and high level of disease severity (PASI 20 at baseline) may not be typical of patients seen in daily clinical practice. Another major concern is that short-term trials provide scanty and sometimes poorly-reported safety data and thus do not provide useful evidence to create a reliable risk profile of treatments. We found no significant difference in the assessed interventions and placebo in terms of SAEs, and the evidence for all the interventions was of low to moderate quality. In order to provide long-term information on the safety of the treatments included in this review, it will also be necessary to evaluate non-randomised studies and postmarketing reports released from regulatory agencies. In terms of future research, randomised trials directly comparing active agents are necessary once high-quality evidence of benefit against placebo is established, including head-to-head trials amongst and between non-biological systemic agents and small molecules, and between biological agents (anti-IL17 versus anti-IL23, anti-IL23 versus anti-IL12/23, anti-TNF alpha versus anti-IL12/23). Future trials should also undertake systematic subgroup analyses (e.g. assessing biological-naïve participants, baseline psoriasis severity, presence of psoriatic arthritis, etc.). Finally, outcome measure harmonisation is needed in psoriasis trials, and researchers should look at the medium- and long-term benefit and safety of the interventions and the comparative safety of different agents. Editorial note: This is a living systematic review. Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
Identifiants
pubmed: 33871055
doi: 10.1002/14651858.CD011535.pub4
pmc: PMC8408312
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Cytokines
0
Immunosuppressive Agents
0
Placebos
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD011535Commentaires et corrections
Type : UpdateOf
Type : UpdateIn
Informations de copyright
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Br J Dermatol. 2019 Jul;181(1):88-95
pubmed: 30734266
Dermatology. 2009;219(3):209-18
pubmed: 19657180
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013
pubmed: 28190255
Chin Med J (Engl). 2012 Jun;125(11):1845-51
pubmed: 22884040
Br J Dermatol. 2011 Jun;164(6):1383-6
pubmed: 21466532
Ter Arkh. 2005;77(8):60-4
pubmed: 16206608
Br J Dermatol. 2017 Sep;177(3):879-881
pubmed: 28498514
N Engl J Med. 2012 Mar 29;366(13):1181-9
pubmed: 22455412
Lancet. 2017 Feb 4;389(10068):528-537
pubmed: 28012564
Zhonghua Nei Ke Za Zhi. 2009 Jul;48(7):570-4
pubmed: 19957798
N Engl J Med. 2007 Feb 8;356(6):580-92
pubmed: 17287478
J Am Acad Dermatol. 2014 Dec;71(6):1176-82
pubmed: 25242558
Br J Dermatol. 2005 Dec;153(6):1192-9
pubmed: 16307657
Br J Dermatol. 2015;172(5):1371-83
pubmed: 25307931
J Eur Acad Dermatol Venereol. 2013 May;27(5):634-42
pubmed: 22429586
J Invest Dermatol. 2005 Jul;125(1):61-7
pubmed: 15982303
J Am Acad Dermatol. 2010 Sep;63(3):457-65
pubmed: 20462664
J Dermatol. 2014 Dec;41(12):1039-46
pubmed: 25354738
J Pak Med Assoc. 2004 Sep;54(9):453-5
pubmed: 15518366
Am J Clin Dermatol. 2019 Feb;20(1):155-164
pubmed: 30417277
Dermatol Online J. 2006 Mar 30;12(3):1
pubmed: 16638415
Br J Clin Pharmacol. 2002 Aug;54(2):147-56
pubmed: 12207634
Semin Arthritis Rheum. 2019 Feb;48(4):632-637
pubmed: 30037432
J Dermatolog Treat. 2015 Feb;26(1):19-22
pubmed: 24289224
J Drugs Dermatol. 2013 Feb;12(2):166-74
pubmed: 23377389
J Clin Aesthet Dermatol. 2018 May;11(5):33-37
pubmed: 29785237
Br J Dermatol. 2017 Mar;176(3):594-603
pubmed: 27292159
J Dermatol. 2016 Aug;43(8):869-80
pubmed: 26875540
Am J Clin Dermatol. 2005;6(6):383-92
pubmed: 16343026
Int J Epidemiol. 2013 Aug;42(4):1120-31
pubmed: 23811232
Dermatology. 2009;219(3):239-49
pubmed: 19752505
Br J Dermatol. 2007 Dec;157(6):1275-7
pubmed: 17916204
Br J Dermatol. 2010 Aug;163(2):402-11
pubmed: 20377585
Int J Dermatol. 2015 Jan;54(1):95-101
pubmed: 25209868
Z Haut Geschlechtskr. 1972 Jul 1;47(13):545-50
pubmed: 4265800
JAMA. 1986 Dec 12;256(22):3110-6
pubmed: 3023712
J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:19-27
pubmed: 21388455
Exp Ther Med. 2018 Dec;16(6):5085-5095
pubmed: 30546410
Br J Dermatol. 2018 Sep;179(3):623-631
pubmed: 29917226
J Am Acad Dermatol. 2015 Jul;73(1):37-49
pubmed: 26089047
Lancet. 2007 Jul 21;370(9583):263-271
pubmed: 17658397
Br J Dermatol. 1989 May;120(5):665-70
pubmed: 2527051
Evid Based Ment Health. 2017 Aug;20(3):88-94
pubmed: 28739577
Ann Rheum Dis. 2020 Jan;79(1):123-131
pubmed: 31563894
Lancet. 2015 Aug 8;386(9993):541-51
pubmed: 26072109
Br J Dermatol. 2017 Apr;176(4):979-984
pubmed: 27858989
Expert Opin Biol Ther. 2017 Mar;17(3):387-394
pubmed: 28165828
J Am Acad Dermatol. 1988 Sep;19(3):458-68
pubmed: 2971692
J Dermatol Sci. 2016 Jan;81(1):44-52
pubmed: 26547109
Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):797-802
pubmed: 20943050
N Engl J Med. 2015 Jul 9;373(2):136-44
pubmed: 26154787
J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7
pubmed: 25769911
J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1763-70
pubmed: 25693783
Lancet. 2008 Apr 19;371(9621):1337-42
pubmed: 18424323
J Am Acad Dermatol. 2008 Jan;58(1):125-35
pubmed: 17996329
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv
pubmed: 17083854
Br J Dermatol. 2017 Apr;176(4):928-938
pubmed: 27787890
Nature. 2015 May 14;521(7551):222-6
pubmed: 25754330
Clin Dermatol. 2010 Jan-Feb;28(1):67-72
pubmed: 20082954
Lancet. 2019 Sep 7;394(10201):831-839
pubmed: 31402114
J Am Acad Dermatol. 2010 May;62(5):812-8
pubmed: 20219265
J Dermatol. 2017 Nov;44(11):1228-1237
pubmed: 28714180
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402
pubmed: 29220542
Lancet. 2009 Feb 21;373(9664):633-40
pubmed: 19217154
J Am Acad Dermatol. 2012 Mar;66(3):369-75
pubmed: 22041254
Br J Dermatol. 1986 Aug;115(2):249-50
pubmed: 3741788
Arch Dermatol. 2009 Apr;145(4):387-93
pubmed: 19380660
Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632
pubmed: 14676082
Drugs Today (Barc). 2012 May;48(5):367-73
pubmed: 22645724
J Invest Dermatol. 2015 Nov;135(11):2641-2648
pubmed: 26046458
Circ Cardiovasc Imaging. 2013 Jan 1;6(1):83-90
pubmed: 23204039
J Am Acad Dermatol. 2018 Apr;78(4):741-748
pubmed: 29066271
Curr Rheumatol Rep. 2006 Oct;8(5):355-63
pubmed: 16973109
J Am Acad Dermatol. 2017 Oct;77(4):667-674
pubmed: 28780364
J Am Acad Dermatol. 2018 Aug;79(2):266-276.e5
pubmed: 29660425
J Dermatol. 2019 Mar;46(3):186-192
pubmed: 30672623
J Invest Dermatol. 2012 Oct;132(10):2466-2469
pubmed: 22622425
Dermatol Ther (Heidelb). 2018 Dec;8(4):571-579
pubmed: 30334147
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):68-72
pubmed: 28881462
Br J Dermatol. 2001 Sep;145(3):438-45
pubmed: 11531834
J Drugs Dermatol. 2012 Aug;11(8):929-37
pubmed: 22859237
J Drugs Dermatol. 2012 Mar;11(3):300-12
pubmed: 22395580
Br J Dermatol. 1997 Dec;137(6):943-9
pubmed: 9470912
J Am Acad Dermatol. 1995 Sep;33(3):470-5
pubmed: 7657870
JAMA Dermatol. 2018 Jun 1;154(6):676-683
pubmed: 29799960
Nat Immunol. 2007 Sep;8(9):950-7
pubmed: 17676044
J Eur Acad Dermatol Venereol. 2010 May;24(5):595-600
pubmed: 20015056
J Am Acad Dermatol. 1995 Jan;32(1):78-88
pubmed: 7822521
J Am Acad Dermatol. 2011 Feb;64(2):263-74
pubmed: 21145618
J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1406-14
pubmed: 25917315
Can J Cardiol. 2020 Jan;36(1):100-111
pubmed: 31606265
J Dermatol. 2019 Aug;46(8):686-694
pubmed: 31237727
Ann Rheum Dis. 2017 Jan;76(1):79-87
pubmed: 27553214
J Drugs Dermatol. 2015 Aug;14(8):821-33
pubmed: 26267726
Clin Exp Dermatol. 2018 Oct;43(7):790-797
pubmed: 29748971
Dermatologica. 1989;178(2):88-92
pubmed: 2522405
J Am Acad Dermatol. 2012 Feb;66(2):e33-45
pubmed: 20850895
Acta Derm Venereol. 1979;59(3):241-4
pubmed: 87082
J Drugs Dermatol. 2017 Aug 1;16(8):801-808
pubmed: 28809995
J Dermatol Sci. 2014 Sep;75(3):201-4
pubmed: 24957501
Br J Dermatol. 2018 Sep;179(3):615-622
pubmed: 29742274
J Am Acad Dermatol. 2017 Aug;77(2):372-374
pubmed: 28711089
J Am Acad Dermatol. 2015 Mar;72(3):436-439.e1
pubmed: 25553889
J Cutan Med Surg. 2009 Sep-Oct;13 Suppl 2:S58-66
pubmed: 19799828
Curr Med Res Opin. 2008 May;24(5):1237-54
pubmed: 18355421
N Engl J Med. 2003 Aug 14;349(7):658-65
pubmed: 12917302
Br J Dermatol. 2012 Sep;167(3):649-57
pubmed: 22533447
N Engl J Med. 2017 Apr 20;376(16):1551-1560
pubmed: 28423301
J Dermatolog Treat. 2019 Feb;30(1):19-26
pubmed: 29726739
J Am Acad Dermatol. 2017 Jan;76(1):70-80
pubmed: 27707593
Br J Dermatol. 2018 Oct;179(4):844-852
pubmed: 29747232
Br J Dermatol. 2017 Dec;177(6):1740-1741
pubmed: 28129675
J Dermatolog Treat. 2020 Mar;31(2):141-146
pubmed: 30799638
J Dermatol Sci. 2017 Oct;88(1):36-45
pubmed: 28558978
Br J Dermatol. 2014 Feb;170(2):435-44
pubmed: 24116868
Br J Dermatol. 2008 Sep;159(3):704-10
pubmed: 18627375
J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9
pubmed: 26660143
Br J Dermatol. 2013 Feb;168(2):412-21
pubmed: 23106107
J Am Acad Dermatol. 2010 Sep;63(3):448-56
pubmed: 20605254
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1930-1939
pubmed: 29633373
Arch Dermatol. 2008 Sep;144(9):1200-4
pubmed: 18794467
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):441-449
pubmed: 32426884
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e305-11
pubmed: 22816881
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2168-2178
pubmed: 31304993
J Am Acad Dermatol. 2001 Nov;45(5):665-74
pubmed: 11606914
Acta Derm Venereol Suppl (Stockh). 1979;59(85):133-6
pubmed: 393035
Br J Dermatol. 2003 Feb;148(2):318-25
pubmed: 12588386
Dermatologica. 1978;157 Suppl 1:32-7
pubmed: 357216
J Dermatol. 2018 Sep;45(9):1053-1062
pubmed: 29905383
JAMA Dermatol. 2016 Jun 1;152(6):661-9
pubmed: 26953848
Br J Dermatol. 2005 Jun;152(6):1219-27
pubmed: 15948985
Br J Clin Pharmacol. 2017 May;83(5):991-1001
pubmed: 27859546
J Eur Acad Dermatol Venereol. 2014 Feb;28(2):192-203
pubmed: 23294276
Br J Dermatol. 2015;172(5):1395-406
pubmed: 25418186
J Am Acad Dermatol. 2008 Jan;58(1):106-15
pubmed: 17936411
Br J Dermatol. 2014 Nov;171(5):1215-9
pubmed: 24749812
Am J Clin Dermatol. 2018 Jun;19(3):457
pubmed: 29600394
Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535
pubmed: 29271481
J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:12-8
pubmed: 21388454
Br J Dermatol. 2020 Feb;182(2):316-326
pubmed: 31206593
J Drugs Dermatol. 2014 May;13(5):554-62
pubmed: 24809878
Br J Dermatol. 2017 Oct;177(4):1033-1042
pubmed: 28580579
Dermatology. 2003;206(4):307-15
pubmed: 12771471
Dermatologica. 1978;157(4):238-44
pubmed: 357213
J Eur Acad Dermatol Venereol. 1998 Nov;11(3):234-9
pubmed: 9883435
J Am Acad Dermatol. 2002 Dec;47(6):821-33
pubmed: 12451365
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552
pubmed: 30242918
Drug Dev Res. 2015 Aug;76(5):215-27
pubmed: 26255795
J Clin Pharmacol. 2009 Feb;49(2):162-75
pubmed: 19179295
Br J Dermatol. 2012 Sep;167(3):668-77
pubmed: 22924949
Br J Dermatol. 2005 Jun;152(6):1304-12
pubmed: 15948997
Eur J Dermatol. 2003 Mar-Apr;13(2):117-23
pubmed: 12695125
J Drugs Dermatol. 2017 Feb 1;16(2):147-153
pubmed: 28300857
Rheumatol Ther. 2015 Jun;2(1):1-16
pubmed: 27747495
J Allergy Clin Immunol. 2012 Jul;130(1):145-54.e9
pubmed: 22677045
J Invest Dermatol. 2008 May;128(5):1207-11
pubmed: 18200064
Acta Derm Venereol Suppl (Stockh). 1989;146:176-7
pubmed: 2532846
Curr Probl Dermatol. 2009;38:107-136
pubmed: 19710553
Int J Dermatol. 2010 Jul;49(7):818-28
pubmed: 20618506
Br J Dermatol. 2020 Apr;182(4):869-879
pubmed: 31376153
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
Br J Dermatol. 2021 Jun;184(6):1047-1058
pubmed: 32880909
Br J Dermatol. 2016 Aug;175(2):273-86
pubmed: 26914406
J Am Acad Dermatol. 2006 Jan;54(1):61-3
pubmed: 16384756
J Am Acad Dermatol. 1992 Oct;27(4):568-74
pubmed: 1401309
J Invest Dermatol. 2018 Oct;138(10):2168-2173
pubmed: 29751001
J Am Acad Dermatol. 2017 Mar;76(3):405-417
pubmed: 28057360
Am J Clin Dermatol. 2003;4(2):131-9
pubmed: 12553852
Br J Dermatol. 2015 Feb;172(2):484-93
pubmed: 25132411
N Engl J Med. 2018 Oct 4;379(14):1313-1321
pubmed: 30205746
J Dermatolog Treat. 2017 Dec;28(8):716-721
pubmed: 28737440
J Eur Acad Dermatol Venereol. 2017 May;31(5):847-856
pubmed: 28111801
Eur J Dermatol. 2011 Sep-Oct;21(5):737-43
pubmed: 21737373
Acta Derm Venereol. 1995 Jan;75(1):65-9
pubmed: 7747540
Arch Dermatol. 2003 Jun;139(6):719-27
pubmed: 12810502
J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1957-1960
pubmed: 27358210
Int J Dermatol. 1988 Nov;27(9):656-60
pubmed: 2976406
Br J Dermatol. 2019 May;180(5):1039-1049
pubmed: 30485400
Br J Dermatol. 1997 Jan;136(1):82-8
pubmed: 9039300
J Dermatol. 2007 Jul;34(7):430-4
pubmed: 17584318
Br J Dermatol. 2008 Jan;158(1):116-21
pubmed: 17986302
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
J Invest Dermatol. 2017 Aug;137(8):1638-1645
pubmed: 28286061
J Dermatolog Treat. 2018 Feb;29(1):8-12
pubmed: 28506134
Clin Exp Dermatol. 2012 Oct;37(7):729-34
pubmed: 22830389
Arch Dermatol. 2004 Mar;140(3):347-8
pubmed: 15023778
J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):681-6
pubmed: 2530251
Health Qual Life Outcomes. 2013 May 10;11:82
pubmed: 23663752
Br J Dermatol. 2015 Jan;172(1):230-8
pubmed: 24861696
Health Technol Assess. 2009 Sep;13 Suppl 2:49-54
pubmed: 19804689
Cutis. 2017 Feb;99(2):123-127
pubmed: 28319618
Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310
pubmed: 27515978
Eur J Dermatol. 2012 Nov-Dec;22(6):762-9
pubmed: 23178916
J Hypertens Suppl. 1998 Sep;16(4):S39-41
pubmed: 9817191
Br J Dermatol. 2014 Feb;170(2):425-34
pubmed: 24116959
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii3-8
pubmed: 15708931
J Dermatolog Treat. 2007;18(5):291-4
pubmed: 17852636
J Drugs Dermatol. 2004 May-Jun;3(3):270-2
pubmed: 15176161
Am J Clin Dermatol. 2003;4(7):507-10
pubmed: 12814339
Arch Dermatol. 2007 Sep;143(9):1113-21
pubmed: 17875871
J Dermatolog Treat. 2022 Feb;33(1):278-283
pubmed: 32233940
J Am Acad Dermatol. 2012 Jul;67(1):86-92
pubmed: 22014541
Acta Derm Venereol. 1989;69(1):35-40
pubmed: 2563606
J Am Acad Dermatol. 2019 Jan;80(1):70-79.e3
pubmed: 29969700
Arch Dermatol. 2012 Dec;148(12):1403-10
pubmed: 23069736
J Dermatol. 2012 Mar;39(3):242-52
pubmed: 21955098
N Engl J Med. 2016 Jul 28;375(4):345-56
pubmed: 27299809
J Dermatolog Treat. 2020 Mar;31(2):152-159
pubmed: 30887876
Dermatologica. 1988;177(4):218-24
pubmed: 2976000
J Dermatol Sci. 2019 Dec;96(3):126-133
pubmed: 31787506
Cochrane Database Syst Rev. 2015 Aug 10;(8):CD010497
pubmed: 26258748
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1693-1699
pubmed: 28602039
J Am Acad Dermatol. 2003 Jan;48(1):68-75
pubmed: 12522373
J Clin Epidemiol. 1997 Jun;50(6):683-91
pubmed: 9250266
Arch Dermatol. 2011 Apr;147(4):429-36
pubmed: 21173304
J Eur Acad Dermatol Venereol. 2011 Jul;25(7):851-7
pubmed: 21521375
J Clin Immunol. 2009 Mar;29(2):210-4
pubmed: 18763027
Adv Ther. 2017 Jun;34(6):1327-1339
pubmed: 28397079
Lancet. 2008 May 17;371(9625):1675-84
pubmed: 18486740
J Dermatol. 2003 Jun;30(6):458-63
pubmed: 12810993
Trials. 2017 Feb 2;18(1):52
pubmed: 28148280
Nat Rev Drug Discov. 2008 Nov;7(11):880-1
pubmed: 18974743
Acta Derm Venereol. 2018 Jan 12;98(1):98-102
pubmed: 28929168
J Am Acad Dermatol. 2020 Nov;83(5):1367-1374
pubmed: 32473974
J Am Acad Dermatol. 2010 Dec;63(6):1011-8
pubmed: 20933301
Br J Dermatol. 2011 Apr;164(4):855-61
pubmed: 21175564
Arch Dermatol. 1966 Jun;93(6):731-6
pubmed: 4222659
J Am Acad Dermatol. 2002 Feb;46(2):242-50
pubmed: 11807436
Dermatology. 2009;219(2):126-32
pubmed: 19546522
Lancet. 2012 Aug 25;380(9843):738-46
pubmed: 22748702
J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:17-24
pubmed: 12795771
Arch Dermatol. 1970 Aug;102(2):144-50
pubmed: 4914264
Br J Dermatol. 2008 Mar;158(3):558-66
pubmed: 18047523
Dermatology. 2016;232(4):407-14
pubmed: 27576483
J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7
pubmed: 29438757
J Am Acad Dermatol. 2012 Feb;66(2):241-51
pubmed: 21752491
Br J Dermatol. 1998 Sep;139(3):380-9
pubmed: 9988537
J Am Acad Dermatol. 2015 Jul;73(1):27-36.e1
pubmed: 25982539
J Eur Acad Dermatol Venereol. 2010 Dec;24(12):1447-51
pubmed: 20384673
Br J Dermatol. 2015 Oct;173(4):949-61
pubmed: 26149717
Dan Med Bull. 1978 Oct;25(5):208-11
pubmed: 359259
Br J Dermatol. 2008 Sep;159(3):513-26
pubmed: 18627372
Int J Cardiol. 2011 Sep 15;151(3):382-3
pubmed: 21764467
J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15
pubmed: 17097378
J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1305-1313
pubmed: 29512200
J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2305-2312
pubmed: 31407394
Lancet. 2008 May 17;371(9625):1639-40
pubmed: 18486724
J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1436-43
pubmed: 22035157
J Am Acad Dermatol. 2006 Mar;54(3):472-8
pubmed: 16488299
Arch Dermatol. 2008 Feb;144(2):200-7
pubmed: 18283176
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028
pubmed: 23543539
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):119-126
pubmed: 31465585
Br J Dermatol. 2012 Apr;166(4):861-72
pubmed: 22356258
J Am Acad Dermatol. 1994 Jun;30(6):977-81
pubmed: 8188891
Lancet. 2008 May 17;371(9625):1665-74
pubmed: 18486739
Br J Dermatol. 2012 Jan;166(1):179-88
pubmed: 21910698
Br J Dermatol. 1999 Aug;141(2):283-91
pubmed: 10468801
Schweiz Rundsch Med Prax. 1981 Oct 6;70(41):1806-16
pubmed: 7312799
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40
pubmed: 24679469
J Eur Acad Dermatol Venereol. 2014 Jul;28(7):900-6
pubmed: 23848989
J Clin Pharmacol. 2010 Mar;50(3):257-67
pubmed: 19934030
Arch Dermatol. 2004 Jun;140(6):685-90
pubmed: 15210458
J Am Acad Dermatol. 2017 Apr;76(4):655-661
pubmed: 28087133
J Am Acad Dermatol. 2017 Nov;77(5):855-862
pubmed: 28917383
J Cutan Med Surg. 2008 Nov-Dec;12(6):268-75
pubmed: 19317948
BMJ. 2010 Feb 02;340:c147
pubmed: 20124563
Health Qual Life Outcomes. 2006 Sep 27;4:71
pubmed: 17005043
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):125-8
pubmed: 22188302
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):89-95
pubmed: 27504914
Br J Dermatol. 2020 Aug;183(2):265-275
pubmed: 31705526
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-427
pubmed: 28960486
Res Synth Methods. 2012 Jun;3(2):111-25
pubmed: 26062085
J Invest Dermatol. 2010 Apr;130(4):933-43
pubmed: 20043014
J Clin Epidemiol. 2011 Feb;64(2):163-71
pubmed: 20688472
Br J Dermatol. 2004 Apr;150(4):630-2
pubmed: 15099356
Arch Dermatol. 2007 Jun;143(6):719-26
pubmed: 17576937
J Dermatol Sci. 2011 Sep;63(3):154-63
pubmed: 21741220
Chin Med J (Engl). 2015 Feb 20;128(4):443-9
pubmed: 25673443
Ann Intern Med. 2013 Jul 16;159(2):130-7
pubmed: 23856683
BMJ. 2013 Apr 24;346:f2304
pubmed: 23616031
N Engl J Med. 2012 Mar 29;366(13):1190-9
pubmed: 22455413
Br J Dermatol. 2005 May;152(5):954-60
pubmed: 15888152
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517
pubmed: 27768242
Br J Dermatol. 2008 Nov;159(5):1177-85
pubmed: 18673365
Cesk Dermatol. 1973 Oct;48(5):301-5
pubmed: 4586960
N Engl J Med. 2016 Nov 24;375(21):2101-2102
pubmed: 27959739
Lancet. 2018 Aug 25;392(10148):650-661
pubmed: 30097359
Dermatologica. 1971;142(3):133-6
pubmed: 4939498
Arch Dermatol Res. 2007 Oct;299(8):359-66
pubmed: 17680257
Br J Dermatol. 2006 Jun;154(6):1161-8
pubmed: 16704649
Lancet. 1983 Mar 26;1(8326 Pt 1):706
pubmed: 6132061
J Dermatol. 2017 Aug;44(8):873-884
pubmed: 28391657
Br J Dermatol. 2021 Mar;184(3):415-424
pubmed: 32446286
J Dermatolog Treat. 2007;18(5):286-90
pubmed: 17852632
Br J Dermatol. 1989 Jul;121(1):107-12
pubmed: 2527054
Lancet. 2006 Jan 7;367(9504):29-35
pubmed: 16399150
Br J Dermatol. 2017 Dec;177(6):1562-1574
pubmed: 28755394
J Am Acad Dermatol. 2013 Sep;69(3):385-92
pubmed: 23643256
Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003
pubmed: 28968735
J Am Acad Dermatol. 2007 Aug;57(2):347-54
pubmed: 17433490
Br J Dermatol. 2015 Feb;172(2):504-12
pubmed: 25288183
Curr Rheumatol Rep. 2009 Aug;11(4):233-4
pubmed: 19691924
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):135-142
pubmed: 32365251
Br J Dermatol. 2018 Jan;178(1):114-123
pubmed: 28635018
Circ Cardiovasc Imaging. 2018 Jun;11(6):e007394
pubmed: 29776990
Arthritis Rheum. 2011 Apr;63(4):939-48
pubmed: 21128258
Trials. 2020 Jan 6;21(1):13
pubmed: 31907007
J Dermatol. 2012 Sep;39(9):761-9
pubmed: 22409383
J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:12-6
pubmed: 12795770
Br J Dermatol. 2012 Dec;167(6):1374-81
pubmed: 22897348
J Clin Pharmacol. 2014 Oct;54(10):1117-24
pubmed: 24752880
Dermatologica. 1990;181(1):33-7
pubmed: 2394301
J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1127-9
pubmed: 24330415
Br J Dermatol. 2017 Oct;177(4):1024-1032
pubmed: 28580646
Dermatology. 2002;205(4):383-8
pubmed: 12444336
Br J Dermatol. 1994 Mar;130(3):366-75
pubmed: 8148280
Br J Dermatol. 2012 Jul;167(1):180-90
pubmed: 22413944
N Engl J Med. 2015 Oct;373(14):1318-28
pubmed: 26422722
J Dermatol. 2017 Nov;44(11):1285-1290
pubmed: 28635026
Hautarzt. 1989 Aug;40(8):486-9
pubmed: 2676910
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482
pubmed: 27910156
Dermatology. 2008;216(1):46-55
pubmed: 18032899
Am J Clin Dermatol. 2011 Feb 1;12(1):51-62
pubmed: 21110526
Circ Cardiovasc Imaging. 2017 Sep;10(9):
pubmed: 28899951
Br J Dermatol. 2013 Apr;168(4):844-54
pubmed: 23301632
Br J Dermatol. 2014 Feb;170(2):398-407
pubmed: 24117389
J Dermatolog Treat. 2015 Feb;26(1):7-15
pubmed: 24283931
Acta Derm Venereol. 2008;88(5):495-501
pubmed: 18779890
Dermatology. 2009;218(2):103-9
pubmed: 19060463
Dermatology. 2005;210(3):194-9
pubmed: 15785046
Br J Dermatol. 2008 Aug;159(2):274-85
pubmed: 18547300
J Eur Acad Dermatol Venereol. 2011 May;25(5):559-64
pubmed: 20840349
J Am Acad Dermatol. 2013 Feb;68(2):341-2
pubmed: 23317974
Lancet. 2014 Dec 6;384(9959):2036-45
pubmed: 25127208
Acta Derm Venereol. 1997 Mar;77(2):137-41
pubmed: 9111826
Cochrane Database Syst Rev. 2021 Apr 19;4:CD011535
pubmed: 33871055
Br J Dermatol. 2007 Jan;156(1):138-42
pubmed: 17199580
Arch Dermatol. 2008 Aug;144(8):1067-8; author reply 1068-9
pubmed: 18711092
J Rheumatol. 2018 Mar;45(3):367-377
pubmed: 29247148
J Am Acad Dermatol. 1991 Apr;24(4):591-4
pubmed: 1827799
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):107-113
pubmed: 27500949
J Am Acad Dermatol. 1991 Oct;25(4):682-4
pubmed: 1838750
J Dermatolog Treat. 2007;18(1):25-31
pubmed: 17365264
Acta Derm Venereol. 2007;87(5):449-50
pubmed: 17721663
Br J Dermatol. 2010 Jan;162(1):137-46
pubmed: 19903183
Br J Dermatol. 2013 May;168(5):1080-7
pubmed: 23013207
Br J Dermatol. 2013 Dec;169(6):1337-41
pubmed: 24032554
Lancet. 2005 Oct 15-21;366(9494):1367-74
pubmed: 16226614
Br J Dermatol. 2006 Jun;154(6):1169-74
pubmed: 16704650
J Am Acad Dermatol. 2012 May;66(5):731-41
pubmed: 21930328
J Dermatolog Treat. 2011 Dec;22(6):323-36
pubmed: 20923370
Aust J Dermatol. 1963 Dec;7:91-2
pubmed: 14148789
J Clin Epidemiol. 2017 Nov;91:23-30
pubmed: 28912002
J Am Acad Dermatol. 2015 Sep;73(3):400-9
pubmed: 26092291
Br J Dermatol. 2017 Oct;177(4):1014-1023
pubmed: 28542874
Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):247-8
pubmed: 15733224
J Sex Med. 2018 Nov;15(11):1645-1652
pubmed: 30415816
Hautarzt. 1994 Jan;45(1):50-2
pubmed: 8150621
Expert Rev Clin Immunol. 2011 Jan;7(1):9-13
pubmed: 21162644
N Engl J Med. 1991 Jan 31;324(5):277-84
pubmed: 1986287
Dermatologica. 1978;157 Suppl 1:38-44
pubmed: 357217
J Invest Dermatol. 2020 Jan;140(1):85-93.e2
pubmed: 31326395
Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):225-9
pubmed: 16569361
J Eur Acad Dermatol Venereol. 2013 Jul;27(7):899-906
pubmed: 22702846
J Dermatolog Treat. 2012 Aug;23(4):255-60
pubmed: 21756153
Eur J Cancer. 2019 Nov;121:19-28
pubmed: 31526874
Am J Clin Dermatol. 2003;4(7):441-7
pubmed: 12814334
Dermatology. 2002;205(1):46-53
pubmed: 12145434
J Rheumatol. 2006 Jul;33(7):1442-6
pubmed: 16724368
Br J Dermatol. 2019 Nov;181(5):954-966
pubmed: 30367462
Br J Dermatol. 2004 Feb;150(2):317-26
pubmed: 14996104
Br J Dermatol. 2015 Oct;173(4):930-9
pubmed: 26042589
Ned Tijdschr Geneeskd. 1990 Dec 8;134(49):2387-91
pubmed: 2263264
Br J Dermatol. 2020 Apr;182(4):889-899
pubmed: 31286480
Br J Dermatol. 2008 Mar;158(3):549-57
pubmed: 18047521
Nat Rev Drug Discov. 2004 Jun;3(6):473-4
pubmed: 15214332
Health Technol Assess. 2009 Jun;13 Suppl 1:55-60
pubmed: 19567215
Lancet. 2017 Jul 15;390(10091):276-288
pubmed: 28596043
Arch Dermatol Res. 2020 Aug;312(6):437-445
pubmed: 31873772
J Dermatol. 2012 Mar;39(3):265-8
pubmed: 22126280
J Am Acad Dermatol. 2005 Nov;53(5):887-9
pubmed: 16243150
Acta Derm Venereol Suppl (Stockh). 1989;146:136
pubmed: 2692368
J Invest Dermatol. 2010 May;130(5):1213-26
pubmed: 19812592
Ann Rheum Dis. 2008 Nov;67(11):1650-1
pubmed: 18854519
Br J Dermatol. 1986 Dec;115(6):745-6
pubmed: 3542010
Indian Dermatol Online J. 2017 Jan-Feb;8(1):16-24
pubmed: 28217466
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):294-303
pubmed: 27515070
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Br J Dermatol. 2017 Mar;176(3):615-623
pubmed: 27515097
J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):311-2
pubmed: 2312814
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):403-410
pubmed: 29055155
Acta Derm Venereol. 2001 Nov-Dec;81(6):429-30
pubmed: 11859949
Br J Dermatol. 2011 Sep;165(3):661-8
pubmed: 21574984
Chin J Integr Med. 2009 Apr;15(2):141-4
pubmed: 19407953
J Invest Dermatol. 2017 Aug;137(8):1646-1654
pubmed: 28457908
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):e1-22
pubmed: 26471228
Br J Dermatol. 2013 Nov;169(5):992-9
pubmed: 23855761
J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:28-33
pubmed: 21388456
Dermatology. 1993;187 Suppl 1:8-18
pubmed: 8369579
J Dermatolog Treat. 2015 Apr;26(2):121-3
pubmed: 24716586
J Invest Dermatol. 2020 Aug;140(8):1546-1555.e4
pubmed: 31972249
J Am Acad Dermatol. 2014 Sep;71(3):484-92
pubmed: 24703722
Acta Derm Venereol. 2020 Jan 7;100(1):adv00006
pubmed: 31620802
J Drugs Dermatol. 2014 Mar;13(3):252-6
pubmed: 24595567
J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5
pubmed: 25773781
J Am Pharm Assoc (2003). 2003 Sep-Oct;43(5):649-50
pubmed: 14626761
J Clin Epidemiol. 2017 Mar;83:65-74
pubmed: 28088593
Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):175-83
pubmed: 15180471
C R Acad Sci III. 1994 Mar;317(3):282-6
pubmed: 7994616
J Am Acad Dermatol. 2017 Jul;77(1):79-87.e1
pubmed: 28396102
J Drugs Dermatol. 2018 Aug 1;17(8):826-832
pubmed: 30124721
Br J Dermatol. 2020 Jun;182(6):1348-1358
pubmed: 31887225
Br J Dermatol. 2018 Jul;179(1):50-53
pubmed: 29399784
Br J Dermatol. 1998 Jul;139(1):88-95
pubmed: 9764154
Int J Dermatol. 2014 Dec;53(12):1531-5
pubmed: 24738793
Ann Univ Mariae Curie Sklodowska Med. 1999;54:173-80
pubmed: 11205760
Clin Exp Rheumatol. 2015 Jan-Feb;33(1):11-9
pubmed: 25535650
J Dermatol. 2011 Oct;38(10):966-72
pubmed: 21545506
Am J Clin Dermatol. 2016 Dec;17(6):691-699
pubmed: 27815915
N Engl J Med. 2003 Nov 20;349(21):2014-22
pubmed: 14627786
Res Synth Methods. 2012 Jun;3(2):98-110
pubmed: 26062084
Australas J Dermatol. 1972 Dec;13(3):93-9
pubmed: 4268882
JAMA Dermatol. 2020 Mar 1;156(3):258-269
pubmed: 32022825
Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5
pubmed: 23013312
Br J Dermatol. 2018 Mar;178(3):689-696
pubmed: 29222947
Stat Med. 2010 Mar 30;29(7-8):932-44
pubmed: 20213715
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514
pubmed: 29444376
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949
pubmed: 29706008
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1515-1522
pubmed: 29512196
J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-7
pubmed: 10459113
Br J Dermatol. 2013 Jul;169(1):137-45
pubmed: 23387374
Int Immunopharmacol. 2019 Aug;73:442-450
pubmed: 31154289
J Dermatolog Treat. 2007;18(6):341-50
pubmed: 18058494
Clin Exp Dermatol. 2010 Oct;35(7):717-22
pubmed: 19925489
J Am Acad Dermatol. 2003 Nov;49(5):816-25
pubmed: 14576659
J Am Acad Dermatol. 2017 Mar;76(3):418-431
pubmed: 28057361
J Dermatol Sci. 2010 Jul;59(1):40-9
pubmed: 20547039
Res Synth Methods. 2012 Jun;3(2):161-76
pubmed: 26062088
Br J Dermatol. 2011 Sep;165(3):652-60
pubmed: 21574983
Nature. 2007 Feb 8;445(7128):648-51
pubmed: 17187052
Acta Derm Venereol Suppl (Stockh). 1989;146:206-7
pubmed: 2532847
Dermatology. 2010;221(2):172-8
pubmed: 20628238
BMC Dermatol. 2016 Jul 25;16(1):11
pubmed: 27455955
J Am Acad Dermatol. 2017 Dec;77(6):1178-1180
pubmed: 29132853
Br J Dermatol. 2017 Mar;176(3):565
pubmed: 28300301
Br J Dermatol. 2011 Nov;165(5):1109-17
pubmed: 21910713
Br J Dermatol. 2017 Mar;176(3):624-633
pubmed: 27416891
J Invest Dermatol. 2020 Sep;140(9):1784-1793.e2
pubmed: 32088207
J Am Acad Dermatol. 2014 Dec;71(6):1183-1190.e3
pubmed: 25313095
J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6
pubmed: 29660421
Br J Dermatol. 1996 Sep;135 Suppl 48:35-9
pubmed: 8881903
Transplant Proc. 1988 Jun;20(3 Suppl 4):32-41
pubmed: 3289211
J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1
pubmed: 28993005
J Am Acad Dermatol. 2012 Oct;67(4):658-64
pubmed: 22281165
J Am Acad Dermatol. 2016 Jan;74(1):134-42
pubmed: 26549249
J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1012-20
pubmed: 21214631
Br J Dermatol. 1990 Nov;123(5):641-7
pubmed: 2248892
J Dermatol. 2017 Apr;44(4):355-362
pubmed: 27726163
Br J Dermatol. 2014 Mar;170(3):705-15
pubmed: 24079852
J Drugs Dermatol. 2012 Aug;11(8):943-9
pubmed: 22859239
J Drugs Dermatol. 2015 Aug;14(8):864-8
pubmed: 26267731
J Am Acad Dermatol. 2020 Jul;83(1):96-103
pubmed: 32032692
J Am Acad Dermatol. 2003 Jun;48(6):829-35
pubmed: 12789171
J Am Acad Dermatol. 2006 Oct;55(4):598-606
pubmed: 17010738
Evid Based Ment Health. 2014 Aug;17(3):85-9
pubmed: 25009175
J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45
pubmed: 23279003
Br J Dermatol. 2016 Aug;175(2):250-62
pubmed: 26919824
Krankenpfl J. 2005;43(7-10):244
pubmed: 16515313
Br J Dermatol. 1972 May;86(5):524-7
pubmed: 4556952
J Dermatolog Treat. 2006;17(1):9-17
pubmed: 16467018
Exp Dermatol. 2015 Jul;24(7):529-35
pubmed: 25828362
J Am Acad Dermatol. 1992 Jan;26(1):86-90
pubmed: 1732342
J Am Acad Dermatol. 2004 Oct;51(4):534-42
pubmed: 15389187
J Drugs Dermatol. 2018 Feb 1;17(2):221-228
pubmed: 29462231
Ann Rheum Dis. 2018 Jun;77(6):890-897
pubmed: 29550766
J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10
pubmed: 29609013
Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S40-5
pubmed: 8811062
J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685
pubmed: 27696577
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9
pubmed: 27663079
J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):237-60
pubmed: 21327538
N Engl J Med. 2010 Jan 14;362(2):118-28
pubmed: 20071701
Lancet. 2001 Jun 9;357(9271):1842-7
pubmed: 11410193
Br J Dermatol. 2011 Aug;165(2):399-406
pubmed: 21564071
J Am Acad Dermatol. 2010 Mar;62(3):427-36
pubmed: 20159310
J Dermatolog Treat. 2018 May;29(3):220-229
pubmed: 28792259
Br J Dermatol. 2017 Aug;177(2):411-418
pubmed: 28196270
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83
pubmed: 23030767
BMC Dermatol. 2015 May 08;15:8
pubmed: 25951857
J Am Acad Dermatol. 2006 Jun;54(6):1013-8
pubmed: 16713455
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):323-332
pubmed: 27600367
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
Trials. 2017 Mar 7;18(1):113
pubmed: 28270175
J Dermatol. 2010 Apr;37(4):299-310
pubmed: 20507398
Br J Dermatol. 1995 Jul;133(1):95-103
pubmed: 7669649
Br J Dermatol. 2021 Jan;184(1):50-59
pubmed: 32594522
Br J Dermatol. 2015 Dec;173(6):1387-99
pubmed: 26357944
J Am Acad Dermatol. 1988 Apr;18(4 Pt 1):655-62
pubmed: 2967310
Eur J Dermatol. 2007 Sep-Oct;17(5):381-6
pubmed: 17673380
Australas J Dermatol. 1972 Aug;13(2):79-83
pubmed: 4566493
J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):423-32
pubmed: 9091474
J Drugs Dermatol. 2018 Oct 1;17(10):1078-1082
pubmed: 30365588
J Invest Dermatol. 2019 May;139(5):1054-1062
pubmed: 30508547
J Rheumatol. 1995 Dec;22(12):2369-70
pubmed: 8965271
Br J Dermatol. 2020 Jul;183(1):60-70
pubmed: 31628677
Br J Dermatol. 1988 Feb;118(2):183-90
pubmed: 3280000
Dermatol Ther. 2017 May;30(3):
pubmed: 28133877
J Clin Epidemiol. 2018 Aug;100:122-129
pubmed: 29432861
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1670-5
pubmed: 24393602
Br J Dermatol. 2008 Jun;158(6):1345-9
pubmed: 18410408
Int J Dermatol. 2011 Oct;50(10):1291-3
pubmed: 21950300
J Am Acad Dermatol. 1989 Jun;20(6):1088-93
pubmed: 2526824
Actas Dermosifiliogr. 2017 Jul - Aug;108(6):550-563
pubmed: 28342534
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90
pubmed: 25243910
J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1415-20
pubmed: 25917214
Int J Epidemiol. 2013 Feb;42(1):332-45
pubmed: 23508418
N Engl J Med. 2001 Jul 26;345(4):248-55
pubmed: 11474662
Stat Med. 2014 Sep 20;33(21):3639-54
pubmed: 24777711
J Am Acad Dermatol. 2016 Jul;75(1):99-105
pubmed: 27021239
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S112-9
pubmed: 16488321
Arch Dermatol Res. 2003 Mar;294(12):559-62
pubmed: 12624782
Arch Dermatol. 2009 Jun;145(6):704-6; discussion 706
pubmed: 19528428
J Int Med Res. 2014 Oct;42(5):1118-22
pubmed: 25143337
J Dermatolog Treat. 2012 Aug;23(4):261-7
pubmed: 21797805
J Dermatolog Treat. 2013 Jun;24(3):169-78
pubmed: 22251226
J Am Acad Dermatol. 2015 Aug;73(2):331-3.e1
pubmed: 26183983
J Am Acad Dermatol. 1994 Jul;31(1):68-74
pubmed: 8021375
PLoS One. 2014 Jul 03;9(7):e99682
pubmed: 24992266
J Am Acad Dermatol. 2017 Jun;76(6):1093-1102
pubmed: 28291552
Pharmacoeconomics. 2010;28(10):935-45
pubmed: 20831302
Health Technol Assess. 2009 Oct;13 Suppl 3:61-6
pubmed: 19846031
Int J Mol Sci. 2017 Nov 25;18(12):
pubmed: 29186830
Br J Dermatol. 2013 Feb;168(2):402-11
pubmed: 23362969
Br J Dermatol. 2018 Jun;178(6):1315-1323
pubmed: 29405255
J Pharmacol Sci. 2019 Apr;139(4):289-303
pubmed: 30922656
Dtsch Med Wochenschr. 1978 Feb 3;103(5):195-9
pubmed: 631039
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1753-1759
pubmed: 27271195
J Dermatolog Treat. 2017 Sep;28(6):492-499
pubmed: 28266243
Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):660-666
pubmed: 29893297
Arthritis Rheum. 2009 Jul;60(7):1884-94
pubmed: 19565495
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
pubmed: 15083780
Arch Dermatol. 1990 Apr;126(4):482-6
pubmed: 2138875
Am J Clin Dermatol. 2017 Apr;18(2):273-280
pubmed: 28074446
Br J Dermatol. 2014 Nov;171(5):1181-8
pubmed: 24734995
J Allergy Clin Immunol. 2016 Apr;137(4):1079-1090
pubmed: 27059729
Lancet. 2019 Aug 17;394(10198):576-586
pubmed: 31280967
J Dermatolog Treat. 2011 Dec;22(6):337-47
pubmed: 21034290
Lancet. 2015 Aug 8;386(9993):552-61
pubmed: 26051365
J Dermatolog Treat. 2007;18(5):279-85
pubmed: 17852631
Br J Dermatol. 2012 Jan;166(1):147-53
pubmed: 21910714
Dermatology. 2017;233(2-3):164-169
pubmed: 28654918
Br J Dermatol. 2017 Dec;177(6):1552-1561
pubmed: 28600818